Medicare has backed away from some of the restrictions it previously proposed for anemia drugs made by Johnson & Johnson and Amgen, which were considered overprescribed. Patient advocacy groups had complained about the restrictions proposed two months ago for J&J's Procrit and Amgen's Epogen and Aranesp. The program won't cover the use of the drugs to treat anemia caused by cancer, only anemia that's related to chemotherapy.

Related Summaries